---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-041709"
form_type: "8-K"
ticker: null
cik: "0000316253"
company_name: "ENZO BIOCHEM INC"
filed_at: "2023-05-22T23:59:59+00:00"
generated_at: "2026-06-14T18:38:11.456984+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Enzo Biochem raises $7M via 10% secured convertible debentures and warrants

## Summary
- Issued $7,608,696 principal amount of 10% OID secured convertible debentures for $7,000,000 net proceeds.
- Warrants to purchase up to 1,000,000 shares at $2.31/share, exercisable for 5 years.
- Debentures mature May 20, 2024; convertible at $3.01/share; interest rises to 18% on default.
- Upon sale of Enzo Clinical Labs to LabCorp, company must prepay $4M or deposit cash collateral.
- Registration rights agreement requires filing by June 19, 2023; liquidated damages if missed.

## SEC filing metadata
- accession: 0001213900-23-041709
- form_type: 8-K
- cik: 0000316253
- company_name: ENZO BIOCHEM INC
- filed_at: 2023-05-22T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/316253/000121390023041709/0001213900-23-041709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/316253/000121390023041709/ea178994-8k_enzobio.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-041709
- JSON: https://secwatch.observer/filing/0001213900-23-041709.json
- Plain text: https://secwatch.observer/filing/0001213900-23-041709.txt

## Key facts
- Debt Financings
  ENZO BIOCHEM INC incurred convertible notes of $7,608,696 with JGB Collateral, LLC, as collateral agent for the Purchasers at 10% per annum maturing May 20, 2024.
  - Instrument: convertible notes
  - Principal: $7,608,696
  - Counterparty: JGB Collateral, LLC, as collateral agent for the Purchasers
  - Rate: 10% per annum
  - Maturity: May 20, 2024
  - Event: incurrence
  source text: the Company agreed to sell to the Purchasers (i) 10% Original Issue Discount Secured Convertible Debentures (the “Debentures”) with an aggregate principal amount of $7,608,696
  evidence_url: https://www.sec.gov/Archives/edgar/data/316253/000121390023041709/0001213900-23-041709-index.htm
- Material Agreements
  ENZO BIOCHEM INC entered into Securities Purchase Agreement with JGB Collateral, LLC, as collateral agent, and the purchasers that are parties thereto valued at aggregate principal amount of $7,608,696 and ... total purchase price of $7,000,000 (effective 2023-05-19).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: JGB Collateral, LLC, as collateral agent, and the purchasers that are parties thereto
  - Value: aggregate principal amount of $7,608,696 and ... total purchase price of $7,000,000
  - Effective: 2023-05-19
  source text: On May 19, 2023, Enzo Biochem, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with each of the purchasers that are parties thereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”) and JGB Collateral, LLC, a Delaware limited liability company, as collateral agent for the Purchasers (the “Agent”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/316253/000121390023041709/0001213900-23-041709-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.